人参茎叶总皂苷联合亚硒酸钠对猪伪狂犬病灭活疫苗免疫的增强作用

为了探讨人参茎叶总皂苷(ginseng stem-leaf saponins,GSLS)联合亚硒酸钠(Na2SeO3,简称Se)对伪狂犬病病毒(PRV)灭活疫苗免疫的增强作用,本试验给小鼠口服GSLS后,接种添加了Se的PRV灭活疫苗,并检测免疫后小鼠血清中PRV gB抗体及其亚类(IgG1和IgG2a)水平、淋巴细胞...     

蜂胶对猪细小病毒灭活疫苗佐剂作用的试验

68只豚鼠随机均分为4组,1³组分别免疫蜂胶、铝胶和油佐剂PPV疫苗,第4组为空白对照组,注射等量生理盐水。免疫后不同时间点采集血清分析特异性血凝抑制抗体效价评价蜂胶佐剂对免疫豚鼠体液免疫的影响,测定淋巴细胞增殖、IL-2和IL-4含量评价蜂胶佐剂对免疫豚鼠细胞免疫的影响。结果表明,蜂胶、油佐剂和铝胶3种佐剂均能提高豚鼠对PPV灭活疫苗的免疫应答能力,油佐剂提高血清HI抗体效果较好,其次为蜂胶佐剂,再次为铝胶佐剂。蜂胶佐剂促进T淋巴细胞增殖和提高IL-2、IL-4、IL-6和IFN-γ含量效果优于油佐剂和铝胶佐剂。结论:蜂胶能增强PPV灭活疫苗的免疫效果。     

Enhancement of the immune response and virological protection of calves against bovine herpesvirus type 1 with an inactivated gE-deleted vaccine

Four immunisation protocols based on inactivated and attenuated commercially available marker vaccines for bovine herpesvirus type 1 (BHV-1) were compared. The first group of calves were vaccinated with an attenuated vaccine administered intranasally and an inactivated vaccine injected subcutaneously, four weeks apart; the second group were vaccinated twice with the attenuated vaccine, first intranasally and then intramuscularly; the third group were vaccinated twice subcutaneously with the inactivated vaccine; and the fourth group were vaccinated twice intramuscularly with the attenuated vaccine. A control group of calves were not vaccinated. The cellular and humoral immune responses were highest in the two groups which received at least one injection of the inactivated vaccine. Virological protection was observed in all the vaccinated groups after a challenge infection and reactivation by treatment with dexamethasone, but the calves which received one dose of the inactivated vaccine as a booster or two doses of the inactivated vaccine excreted significantly less of the challenge virus than the calves which were vaccinated only with the attenuated preparation.     

Humoral immune response of the bovine fetus to in utero vaccination with attenuated bovine coronavirus

A fetal response to in utero vaccination with attenuated bovine coronavirus (9 to 49 days before parturition) was determined in 8 calves, 5 vaccinated and 3 controls. Calves were derived by hysterotomy before parturition and were maintained in a closed gnotobiotic environment. The IgA, IgM, and IgG values and coronavirus-neutralizing antibody titers were higher in the sera and intestinal loop fluid from vaccinated calves than in those from control calves. Sections of ileum and ileal lymph nodes from 1-day-old vaccinated calves, when stained with monospecific anti-bovine IgG, IgM, and IgA had numerous positively stained plasma cells. Positive fluorescence was not detected in comparable tissues from controls. When the 8 calves were given virulent coronavirus orally at 6 days of age, vaccinated calves did not become ill, whereas control calves had diarrhea in 19 to 22 hours. All calves were killed at 10 days of age. Control calves had lesions characteristic of coronavirus infection, and intestinal epithelial cells were positive by fluorescent antibody tests. In vaccinated calves, lesions of coronavirus infection were absent, and results of fluorescent antibody tests were negative. Although in utero vaccination with a coronavirus vaccine stimulated immunity in the newborn calf, the frequency of abortions (2 of 14 cows inoculated intra-amniotically) and premature births (4 of 14) precluded practical application.     

人参皂甙Re对兽用狂犬病灭活疫苗的佐剂作用

大量研究表明从人参中提取的人参皂甙Re(Re)具有提高机体免疫功能的作用,显示了良好的免疫佐剂活性,但其对兽用狂犬病灭活苗(RV)在犬上的免疫佐剂活性研究鲜有报道。本试验将比格犬随机分成RV(1头份)组和RV(1头份)+Re(100μg/只)组,在免疫前1周和免疫后1,4,8,16周采血,进行血清特异性抗体和外周血淋巴细胞CD4+/CD8+值的检测。结果表明,RV+Re试验组能显著提高血清特异性抗体水平,并明显延长了血清特异性抗体的持续时间,提高了CD4+/CD8+值。提示Re作为佐剂能增强机体对抗原的免疫应答,提高RV疫苗的免疫效果。     

Cell-mediated immune response in cattle to bovine respiratory syncytial virus

Cattle inoculated with bovine respiratory syncytial virus (BRSV) were evaluated for the development of a cell-mediated immune response. Results of the leukocyte migration-inhibition test under agarose and the delayed hypersensitivity test indicated that a cell-mediated immune response was elicited after intranasal inoculation of calves with BRSV. Migration inhibition in the leukocyte migration-inhibition test was detected by postinoculation day (PID) 5 and reached maximum inhibition on PID 21. Inhibition of leukocyte migration was still evident by PID 42 when values were still appreciably greater than preinoculation values. All of the calves inoculated with BRSV developed a delayed hypersensitivity skin response when challenge exposed intradermally with BRSV antigen.     

Immunity to canine adenovirus respiratory disease: effect of vaccination with an inactivated vaccine

Nine puppies without maternal antibody to canine adenovirus (CAV) were divided into two groups. The first consisted of six puppies, each of which was given two doses of a commercial inactivated CAV-1 vaccine, 14 days apart. Eight days after administration of the second dose of vaccine, all six puppies, together with the second group, consisting of three unvaccinated controls, were challenged with an aerosol of virulent CAV-2. One dog from each group was killed on the third, fifth and 10th days after challenge and the three additional vaccinates killed at intervening times. All of the dogs developed respiratory signs, mainly coughing and tachypnoea, but the vaccinated dogs made a more rapid recovery. The lungs of both groups were consolidated, the areas affected being more extensive in the controls, and histological examination revealed the main lesion to be a severe necrotising bronchiolitis. Virus was isolated from the respiratory tissues and from throat swabs collected from both groups of dogs. The presence of neutralising antibody in the serum was not, of itself, sufficient to control viral replication and oblate the disease.     

Lack of evidence for an association between MHC diversity and the development of bovine neonatal pancytopenia in Holstein dairy cattle

Bovine neonatal pancytopenia (BNP), a disease of neonatal calves, has been described in a number of European countries since 2006. The disease results in high mortality of calves aged 1-4 weeks and is characterised by severe bone marrow pathology resulting in profound thrombocytopenia and consequent haemorrhagic diathesis. A number of hypotheses including a novel virus infection, plant toxins, a vaccine associated isoimmune disease, or a genetic defect have been suggested to explain the aetiology of this disease. However, as the number of cases in affected herds remains small, it is hypothesised that the genetic background of the calf may influence disease susceptibility. To test this we focused on the class II region of the major histocompatibility complex (MHC) which is often associated with variations in immune response and susceptibility to antibody mediated autoimmune disease. Forty-three cases of BNP and sixty-eight controls were genotyped at the polymorphic class II MHC-DRB3 locus. Twenty DRB3 alleles were identified with seven appearing at frequencies ≥ 0.05. A comparison of the allelic frequencies between diseased and control groups showed that there was no evidence for any significant differences, suggesting that the MHC does not appear to be a predisposing risk factor in the development of BNP in Holstein dairy cattle.     

Experiements with an inactivated hepatitis leptospirosis vaccine in vaccination programmes for dogs.

A fluid adjuvanted vaccine consisting of inactivated hepatitis virus (iH) and leptospirae antigens (L) was developed. The vaccine (Kavak iHL; Duphar) was tested in several vaccination programmes both alone and in combination with freeze dried measles (M) or distemper (D) vaccines. The results demonstrate that this new vaccine is also effective in pups with maternally derived antibodies, although a second vaccination at 14 weeks of age is recommended to boost the first vaccination. For the booster vaccination either the iHL-vaccine or the liver attenuated hepatitis vaccine (H) can be used.     

Serologic responses of pregnant thoroughbred mares to vaccination with an inactivated equine herpesvirus 1 vaccine

The immunogenic potency and safety of a chemically inactivated equine herpesvirus 1 vaccine with added adjuvant was evaluated by testing serum-neutralizing and complement-fixation antibody responses of pregnant Thoroughbred mares. The vaccinated population comprised 321 pregnant mares on 7 farms; 3 in Normandy, France; 1 in Kildare, Ireland; and 3 in central Kentucky. The pattern of antibody response to vaccination was found qualitatively and quantitatively similar to that of pregnant mares previously vaccinated and determined by challenge exposure to be immune to abortigenic infection under experimentally controlled conditions. The safety of the vaccine was demonstrated by the occurrence of only 2 local untoward reactions to the administration of 941 IM injections.     

The anamnestic serologic response to vaccination with a canarypox virus-vectored recombinant West Nile virus (WNV) vaccine in horses previously vaccinated with an inactivated WNV vaccine

A new recombinant West Nile virus (WNV) vaccine has been licensed for use in horses. Prior to the availability of the recombinant vaccine in 2004, the only equine WNV vaccine available on the market had been an inactivated vaccine. Since the recombinant vaccine only expresses selected viral genes, the question could be posed as to whether a single dose of the recombinant vaccine would be effective in producing an anamnestic serologic response in horses previously vaccinated with an inactivated WNV vaccine. In this study we demonstrate that vaccination of horses with a canarypox-vectored recombinant vaccine, under field conditions, results in a marked anamnestic response in horses previously vaccinated with an inactivated WNV vaccine.     

狂犬病灭活疫苗CVS-11株对牛的免疫效果

野生狐和貉狂犬病流行于新疆、内蒙古和黑龙江地区,是当地牛、羊和骆驼等家畜狂犬病的主要传染源。在国内尚无野生动物口服疫苗的前提下,对家畜进行狂犬病灭活疫苗接种,具有重要的公共卫生学意义。本研究利用国产犬用狂犬病灭活疫苗(CVS-11株)对牛进行了免疫效果和安全性评价。以不同剂量疫苗肌内注射免疫成年牛350头,通过比较免疫后狂犬病病毒中和抗体水平和持续期,确定犬用狂犬病灭活疫苗(CVS-11株)在牛的最佳免疫剂量为1次性注射2剂量疫苗,免疫持续期为1年。结果表明,犬用狂犬病灭活疫苗(CVS-11株)免疫牛时,具有较高的免疫原性和安全性,适用于牛等大型动物的狂犬病注射免疫。     

Fetal protection against continual exposure to bovine viral diarrhea virus following administration of a vaccine containing an inactivated bovine viral diarrhea virus fraction to cattle

OBJECTIVE: To evaluate the efficacy of a commercially available killed bovine viral diarrhea virus (BVDV) vaccine to protect against fetal infection in pregnant cattle continually exposed to cattle persistently infected with the BVDV. ANIMALS: 60 crossbred beef heifers and 4 cows persistently infected with BVDV. PROCEDURES: Beef heifers were allocated to 2 groups. One group was vaccinated twice (21-day interval between the initial and booster vaccinations) with a commercially available vaccine against BVDV, and the other group served as nonvaccinated control cattle. Estrus was induced, and the heifers were bred. Pregnancy was confirmed by transrectal palpation. Four cows persistently infected with BVDV were housed with 30 pregnant heifers (15 each from the vaccinated and nonvaccinated groups) from day 52 to 150 of gestation. Fetuses were then harvested by cesarean section and tested for evidence of BVDV infection. RESULTS: 1 control heifer aborted after introduction of the persistently infected cows. Bovine viral diarrhea virus was isolated from 14 of 14 fetuses obtained via cesarean section from control heifers but from only 4 of 15 fetuses obtained via cesarean section from vaccinated heifers; these proportions differed significantly. CONCLUSIONS AND CLINICAL RELEVANCE: A commercially available multivalent vaccine containing an inactivated BVDV fraction significantly reduced the risk of fetal infection with BVDV in heifers continually exposed to cattle persistently infected with BVDV. However, not all vaccinated cattle were protected, which emphasizes the need for biosecurity measures and elimination of cattle persistently infected with BVDV in addition to vaccination within a herd.     

Assessment of efficacy of a bivalent BTV-2 and BTV-4 inactivated vaccine by vaccination and challenge in cattle

The efficacy of a bivalent inactivated vaccine against bluetongue virus (BTV) serotypes 2 (BTV-2) and 4 (BTV-4) was evaluated in cattle by general and local examination, serological follow-up, and challenge. Thirty-two 4-month-old calves were randomly allocated into 2 groups of 16 animals each. One group was vaccinated subcutaneously (s/c) with two injections of bivalent inactivated vaccine at a 28-day interval, and the second group was left unvaccinated and used as control. Sixty-five days after first vaccination, 8 vaccinated and 8 unvaccinated calves were s/c challenged with 1 mL of 6.2 Log10 TCID50/mL of an Italian field isolate of BTV serotype 2, while the remaining 8 vaccinated and 8 unvaccinated animals were challenged by 1 mL of 6.2 Log10 TCID50/mL of an Italian field isolate of BTV serotype 4. Three additional calves were included in the study and used as sentinels to confirm that no BTV was circulating locally. At the time of the challenge, only one vaccinated animal did not have neutralizing antibodies against BTV-4, while the remaining 15 showed titres of at least 1:10 for either BTV-2 or BTV-4. However, the BTV-2 component of the inactivated vaccine elicited a stronger immune response in terms of both the number of virus neutralization (VN) positive animals and antibody titres. After challenge, no animal showed signs of disease. Similarly, none of the vaccinated animals developed detectable viraemia while bluetongue virus serotype 2 and 4 titres were detected in the circulating blood of all unvaccinated animals, commencing on day 3 post-challenge and lasting 16 days. It is concluded that administration of the bivalent BTV-2 and BTV-4 inactivated vaccine resulted in a complete prevention of detectable viraemia in all calves when challenged with high doses of BTV-2 or BTV-4.